Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients (GENIALL)
Glybera Registry, Long-term Safety and Efficacy Follow-up in Lipoprotein Lipase Deficient (LPLD) Patients Treated With Alipogene Tiparvovec (GLYBERA®)
Sponsor: UniQure Biopharma B.V.
Listed as NCT03293810, this observational or N/A phase trial focuses on Familial Hyperchylomicronemia and Familial Hyperlipoproteinemia Type 1 and remains completed. Sponsored by UniQure Biopharma B.V., it has been updated 13 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2022 — Dec 2023 [monthly]
Active Not Recruiting
-
May 2021 — Jun 2022 [monthly]
Active Not Recruiting
▶ Show 8 earlier versions
-
Feb 2021 — May 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — Feb 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Recruiting NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UniQure Biopharma B.V.
For direct contact, visit the study record on ClinicalTrials.gov .